文献速递妇科

早期宫颈癌临床与病理肿瘤大小不一致:是否有影响

Pathologic and clinical tumor size discordance in early-stage cervical cancer: Does it matter?
PubMed 文献 · Gynecol Oncol · 2020-09-02

该研究为多机构回顾性二次分析,纳入2010至2017年接受根治性子宫切除术的630例FIGO 2009分期IB1期宫颈癌患者,77例(12%)病理升级为肿瘤>4 cm。病理升级与辅助治疗几率增加(88% vs 29%,OR 18.49,95%CI 8.99-37.94)、复发风险(HR 1.95,95%CI 1.03-3.67)及全因死亡风险(HR 2.31,95%CI 1.04-5.11)升高相关。

要点

  • 630例IB1期宫颈癌中77例(12%)病理肿瘤大小>4 cm,发生病理升级。
  • 病理升级者接受辅助治疗比例88%,肿瘤≤4 cm者为29%(OR 18.49,95%CI 8.99-37.94)。
  • 病理升级与复发风险(HR 1.95,95%CI 1.03-3.67)及全因死亡风险(HR 2.31,95%CI 1.04-5.11)升高相关。

核心结论

  • IB1期宫颈癌病理升级相对常见,与辅助治疗、复发和全因死亡风险增加相关。
  • 术前锥切和肿瘤<2 cm者病理升级风险较低。
  • 改善术前肿瘤大小评估可能更好地指导初始治疗决策。

研究设计与样本

  • 对先前多机构回顾性综述的二次分析,纳入2010至2017年接受根治性子宫切除术的FIGO 2009分期IB1期宫颈癌患者630例。
  • 病理升级定义为术前诊断IB1期而病理显示肿瘤大小>4 cm。

主要发现

  • 630例中77例(12%)发生病理升级。
  • 病理升级组术前锥切率较低(p < .001),术前肿瘤≤2 cm者比例较低(p < .001)。
  • 病理升级组深间质浸润、淋巴血管间隙浸润、切缘阳性和淋巴结阳性的几率增加。
  • 病理升级组88%接受辅助治疗,肿瘤≤4 cm组为29%(OR 18.49,95%CI 8.99-37.94)。
  • 病理升级与复发风险升高(HR 1.95,95%CI 1.03-3.67)和全因死亡风险升高(HR 2.31,95%CI 1.04-5.11)相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to assess the rate of discordance between clinical and pathologic tumor size for women with stage IB1 cervical cancer (FIGO 2009 criteria), assess risk factors for discordance, and determine the impact of discordance on oncologic outcomes. METHODS: This was a secondary analysis of a prior multi-institutional retrospective review of patients diagnosed with stage IB1 (FIGO 2009 staging) cervical cancer undergoing radical hysterectomy between 2010 and 2017. Demographic, clinicopathologic, and oncologic data were collected. Pathologic upstaging was defined as having a preoperative diagnosis of stage IB1 cervical cancer with pathology demonstrating a tumor size >4 cm. Demographic and clinicopathologic data was compared using chi-square, fisher exact or 2-sided t-test. Survival was estimated using the Kaplan-Meier method. RESULTS: Of the 630 patients, 77 (12%) were upstaged. Patients who were upstaged had lower rates of preoperative conization (p < .001) or preoperative tumor sizes ≤2 cm (p < .001). Upstaged patients had increased odds of deep stromal invasion, lymphovascular space invasion, positive margins and positive lymph nodes. Almost 88% of upstaged patients received adjuvant therapy compared to 29% of patients with tumors ≤4 cm (odds 18.49, 95% CI 8.99-37.94). Finally, pathologic upstaging was associated with an increased hazard of recurrence (hazard ratio [HR] 1.95, 95% CI 1.03-3.67) and all-cause death (HR 2.31, 95% CI 1.04-5.11). CONCLUSIONS: Pathologic upstaging in stage IB1 cervical cancer is relatively common. Upstaging is associated with an 18-fold increased risk of receipt of adjuvant therapy. Patients undergoing preoperative conization and those with tumors <2 cm had lower risks of upstaging. Improvement in preoperative assessment of tumor size may better inform primary treatment decisions.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Vetter MH, Smrz S, Gehrig PA, et al. Pathologic and clinical tumor size discordance in early-stage cervical cancer: Does it matter? Gynecol Oncol. 2020. PMID: 32888724. doi:10.1016/j.ygyno.2020.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。